Most pharma wins arent won in court. Theyre won in the math.
Heres the hard truth: drug patent settlements are often treated like a default strategya clean, predictable way to buy time, avoid litigation costs, and move on.
But default can become expens…

Device patents dont break first because theyre weaker. They break first because the system around them is built to test themfast, publicly, and with full legal leveragebefore the rest of the fortress ever gets close to trial.
Thats the real lesson from…

A patent just changedand somehow youre the one who pays.
In generic drug markets, the public story is simple: once a brands patent expires, competition arrives and prices fall.
But the lived reality is messier. Sometimes the expiration date comes and g…

Six months sounds like protection.
It isnt.
For too long, the pediatric exclusivity clock has been treated as a tidy policy winan add-on to spur childrens studies while keeping generic and biosimilar competition at bay. But the more the system gets str…

Bausch Health vs. Sun Pharma: The Patent Fight That Could Reshape Leverage in Generic Competition
In high-stakes pharma litigation, the fight is rarely just about one patent. Its about controlof timelines, bargaining power, and the next step in the lif…

🚨 Breakthrough therapies dont fail because the science is weakthey get delayed because the clock runs out first.
That tension sits at the center of Exelixis v. Intas Pharmaceuticals, the dispute highlighted in DrugPatentWatchs latest analysis. While…

🚨 A $ and a precedent are on the line in Amneal Pharmaceuticals LLC v. Alembic Pharmaceuticals Ltd. (DrugPatentWatch blog)
If youve been watching the quiet chess match between brand and generic drug makers, this case deserves your attentionbecause …

Exelixis v. Handa: The Quiet Battlefield Where Patent Wins Get Decodedand Why It Matters to Investors
If you blinked, you may have missed itbut the Exelixis v. Handa dispute is exactly the kind of case that doesnt just decide a legal outcome. It can de…

Takeda just scored a win in a fight that matters far beyond the courtroom.
In a decision covered in DrugPatentWatch, Takeda Pharmaceuticals U.S.A., Inc. v. Sun Pharmaceutical Industries Ltd. highlights a reality that brand and generic players both know…

A quiet courtroom fight can move markets faster than most headlines.
In todays post, DrugPatentWatch breaks down Azurity Pharmaceuticals, Inc. v. Aurobindo Pharma Limiteda patent dispute that may look niche on the surface, but is deeply consequential f…